LivaNova opened lower at $90.91, compared with its previous close of $90.98. In the last trading session, the stock traded between $89.84 and $91.32. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in LivaNova is now worth
$ 101.41
Giving a profit of
$ 1.41 (1.41%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
85.71%
Hold
14.29%
Sell
0%
Markets Today
Today's Change
$-0.83 (-0.92%)
Day High
$91.32
Day Low
$89.84
Day Open
$90.91
Prev Close
$90.98
Volume
2,93,876
1W Return
-4.31%
1M Return
16.51%
3M Return
14.66%
6M Return
28.61%
1Y Return
71.12%
Fundamentals
Market Cap ($ Mn)
4,966
PE Ratio
23.77
PB Ratio
3.34
PEG Ratio
-
ROE
-20.78%
ROCE
-10.42%
EPS (TTM)
$0.62
Investment Returns
1 Week
-4.31%
1 Month
16.51%
3 Months
14.66%
6 Months
28.61%
9 Months
35.70%
Financials
Quarterly
All values in $ Mn
352.5
Jun 25
357.8
Sep 25
360.9
Dec 25
362.3
Mar 26
390.6
Jun 26
393.1
Sep 26
Updates
5Nov
Needham raises LivaNova price target to $112, maintains Buy rating
Needham raises LivaNova price target from $93 to $112. Analyst Mike Matson maintains a Buy rating on the stock. Price target increased by $19 per share.
LivaNova raised FY26 adjusted EPS guidance to $4.40-$4.50, beating the $4.37 analyst estimate. FY26 sales outlook increased to $1.513 billion-$1.527 billion, exceeding the $1.522 billion consensus. Q3 adjusted EPS of $1.23 beat estimates by 16.04%, with sales up 9.87% YoY to $393.1 million.
8 days ago
23Oct
LivaNova publishes 36-month CORE-VNS trial results in journal
LivaNova PLC announced publication of 36-month CORE-VNS study results. Study is first long-term effectiveness evaluation of contemporary VNS Therapy for DRE. Findings published in journal Neuromodulation: Technology at the Neural Interface. Research covers full international cohort for extensive long-term outcome data.
20 days ago
16Jul
Mizuho raises LivaNova price target to $95
Mizuho analyst Anthony Petrone maintained an Outperform rating on LivaNova (NASDAQ: LIVN) and raised the price target from $90 to $95, indicating a positive outlook for the stock.
4mo ago
1Jul
Freedom Capital Markets initiates LivaNova coverage with Hold rating
Freedom Capital Markets analyst Keith Hinton initiated coverage on LivaNova with a Hold rating and a price target of $81.
4mo ago
24Jun
LivaNova to announce second-quarter 2026 results on Aug 5
LivaNova PLC will release its second-quarter 2026 results on Aug. 5, 2026, followed by a conference call at 1 p.m. London time. Access is available via webcast and telephone, with a replay offered on the company's website.
